-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Pw8+d/p+ZfPVnA+wYeoAql2m/026os0iZgQpR0ePoTsMZb2NGTWbBCzxUDit5eRF
 N/+e5E/AvOobwtbFSL2qeQ==

<SEC-DOCUMENT>0000105770-04-000677.txt : 20041227
<SEC-HEADER>0000105770-04-000677.hdr.sgml : 20041224
<ACCEPTANCE-DATETIME>20041227151312
ACCESSION NUMBER:		0000105770-04-000677
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041227
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Material Impairments
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041227
DATE AS OF CHANGE:		20041227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			WEST PHARMACEUTICAL SERVICES INC
		CENTRAL INDEX KEY:			0000105770
		STANDARD INDUSTRIAL CLASSIFICATION:	FABRICATED RUBBER PRODUCTS, NEC [3060]
		IRS NUMBER:				231210010
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08036
		FILM NUMBER:		041226330

	BUSINESS ADDRESS:	
		STREET 1:		101 GORDON DR
		STREET 2:		P O BOX 645
		CITY:			LIONVILLE
		STATE:			PA
		ZIP:			19341-0645
		BUSINESS PHONE:		6105942900

	MAIL ADDRESS:	
		STREET 1:		101 GORDON DRIVE
		STREET 2:		PO BOX 645
		CITY:			LIONVILLE
		STATE:			PA
		ZIP:			19341-0645

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WEST CO INC
		DATE OF NAME CHANGE:	19990405
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fille8k.htm
<DESCRIPTION>FILE8K
<TEXT>
<HTML>
<HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">
<FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5">
<B>FORM 8-K </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<HR WIDTH="17%"SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">
<B>CURRENT REPORT</B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">
<B>PURSUANT TO SECTION 13 OR 15(d)<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">
<B>Date of Report (Date of Earliest Event Reported) &#150; December 27, 2004 </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>
WEST PHARMACEUTICAL SERVICES, INC.<BR>
<BR><FONT FACE="Times New Roman" SIZE="3"></FONT>
(Exact name of registrant as specified in its charter) </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center"> <TR> <TD WIDTH="34%"></TD> <TD
VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="32%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD
WIDTH="32%"></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Pennsylvania</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1-8036</B></FONT></TD> <TD VALIGN="bottom"><FONT
SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>23-1210010</B></FONT></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other
jurisdiction<BR>
of Incorporation)</B></FONT></P>
</TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top" ALIGN="center"> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS
Employer</B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P>
</TD></TR> </TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center"> <TR> <TD WIDTH="50%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD>
 <TD WIDTH="48%"></TD></TR> <TR> <TD VALIGN="top" ALIGN="center">
<FONT FACE="Times New Roman" SIZE="2"><B>101 Gordon Drive, PO Box 645, Lionville, PA</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD
VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>19341-0645</B></FONT></TD></TR> <TR> <TD
VALIGN="top" ALIGN="center">

<FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive
offices)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR> </TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">
<B>610-594-2900</B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not Applicable
</B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>(Former name or address, if changed since last report) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px">

<FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <p Style='page-break-before:always'>




<!-- MARKER FORMAT-SHEET="Para Hang" FSL="Default" -->
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A001></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 1.01 Entry into a
Material Definitive Agreement. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On December 24, 2004, West
Pharmaceutical Services, Inc (&#147;West&#148;) entered into a Share and Asset Purchase
Agreement (the &#147;Agreement&#148;) to sell its Drug Delivery business to a new company
formed by Warburg Pincus Private Equity VIII and Warburg Pincus International Partners to
facilitate the acquisition. As announced on June 30, 2004, West intends to concentrate
resources on its core Pharmaceutical Systems business and was evaluating strategic
alternatives for the Drug Delivery business that would provide for its near term funding
needs and long term success. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Under the terms of the Agreement, the
new company will purchase all of the shares of West&#146;s wholly owned subsidiary in
Nottingham, United Kingdom and certain assets in the United States which collectively
represent West&#146;s Drug Delivery business. The Drug Delivery business consists of the
business of researching, developing, licensing and marketing systems for the delivery of
therapeutic compounds for sale throughout the world covering a range of delivery technologies
for various types of administration, including, nasal, oral and parenteral, and products
that incorporate these technologies in each case that employ West's patented or
proprietary chitosan or pectin nasal technology or starch-capsule coating oral technology
and the business of developing a generic manually administrable fluticasone product.
At the closing date of the Agreement, West
will receive cash proceeds of $7.1 million and a 14% ownership interest in the new
company. In addition, West is entitled to 3% of any future royalty income resulting from
the commercial success of the technologies contributed to the new company. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>As a result of the transaction, West
will record a pre-tax charge in the range of $4.0 million to $7.0 million ($0.08 to
$0.16 per diluted share) consisting of severance, transaction and other exit costs
estimated at $3.9 million and potential asset impairment charges. The results of the Drug
Delivery Systems segment, including the loss on disposal, will be reported as discontinued
operations in West&#146;s subsequent financial reports. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Agreement is subject to customary
closing conditions, which are expected to be satisfied within 30 days of the signing of
the agreement. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On December 27, 2004, West issued a
press release announcing the signing of the Agreement. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by
reference. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A002></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 2.05 Costs
Associated with Exit or Disposal Activities. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information contained in item
1.01 above is hereby incorporated by reference. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;
          In connection with the Agreement to sell the Drug Delivery business to the new
          company, West will incur employee termination and other exit costs, primarily in
          the United States related to operations that will not be assumed by the new
          company. These actions will be completed by December 31, 2004. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>b)&nbsp;&nbsp;&nbsp;&nbsp;
          The major costs expected to be incurred in connection with the Agreement are
          listed below: </FONT></P>
<pre>
Severance costs                                      $1.9 million
Legal fees and other transaction costs               $1.0 million
Pension plan curtailment charge                      $0.5 million
Contract termination and laboratory exit costs       $0.5 million
</pre>
<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>c)&nbsp;&nbsp;&nbsp;&nbsp;
          The total costs associated with the Agreement to dispose of the Drug Delivery
          business are estimated at $3.9 million. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>d)&nbsp;&nbsp;&nbsp;&nbsp;
          West estimates that $2.9 million of the costs expected to be incurred will be
          paid in cash. The remaining $1.0 million of non-cash charges are associated with
          stock based severance compensation and pension plan curtailment charges. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A003></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 2.06 Material
Impairments. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information contained in item
1.01 and 2.05 above is hereby incorporated by reference. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;
          On December 24, 2004 West agreed to sell its Drug Delivery business to a new
          company in return for cash and a 14% ownership interest in the new company. In
          addition, West has also determined that it will dispose of its Clinical Services
          unit component of the Drug Delivery segment and has classified those assets as
          being held for sale or other disposition. Preliminary analysis of the fair value
          of the Clinical Services business, the 14% interest in the new company and the
          recovery value of certain equipment retained by West has been performed
          indicating a maximum pre-tax impairment charge of $3.1 million. The final
          determination of the impairment charge, if any, will be made upon the completion
          of the fair value analysis and any related disposition agreements. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->

<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Item
9.01 Financial Statements and Exhibits.</FONT></H1>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(c)&nbsp;&nbsp;&nbsp;&nbsp;
          Exhibits </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left" FSL="Default" -->
<A NAME=A005></A>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;99.1
Press Release dated December 27, 2004 </FONT></P>

<BR>

<HR SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0"WIDTH="40%" BORDER="0"> <TR> <TD WIDTH="100%"></TD></TR> <TR> <TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><u>

WEST PHARMACEUTICAL SERVICES</u></FONT></P><br> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">
/s/ Joseph E. Abbott</FONT></P>
<HR WIDTH="72%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR> <TR> <TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">

Joseph E. Abbott</FONT></TD></TR> <TR> <TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">
Vice President and Corporate Controller</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">December 27, 2004 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<HR SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Exhibit Index</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.1&nbsp;&nbsp;&nbsp;&nbsp;
West Pharmaceutical Services, Inc. Press Release, dated December 27, 2004. </FONT></P>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh99.htm
<DESCRIPTION>EXHIBIT 99.1 DRUG DELIVERY
<TEXT>
<HTML>
<HEAD>
<TiTLE> exhibit 99.1 </title>
</HEAD>
<body>
<BR>
<!-- MARKER FORMAT-SHEET="Head Sub 1 Left" FSL="Default" -->
<A NAME=A001></A>
<P ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit 99.1</FONT></P>
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><B>&nbsp;&nbsp;&nbsp;WEST
PHARMACEUTICAL SERVICES CONCLUDES DRUG DELIVERY <BR>STRATEGIC REVIEW</B> </FONT></P>

<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Warburg Pincus forms new company to acquire and finance Drug Delivery Business<BR>
Conference call is scheduled for tomorrow, December 28 at 3:00 P.M. (E.S.T.) -</FONT></P>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>LIONVILLE, Pa., December 27, 2004
&#151; West Pharmaceutical Services, Inc. (NYSE: WST), the global market leader in closure
systems and syringe components for use with injectable drugs, today announced that it has
signed a definitive agreement to sell a substantial majority interest in its Drug Delivery
business to a new company formed by Warburg Pincus to facilitate the acquisition. Closing
is expected to occur early in 2005. Under the agreement, West will transfer substantially
all of its technology-related Drug Delivery assets and receive $7.1 million in cash and
approximately 14% of the stock of the new company. In addition, West is entitled to earn
up to $19 million of contingent payments, based on royalties or other net profits earned
by the new company from West&#146;s technologies. Warburg Pincus has agreed to provide $40
million of new capital in two stages in order to finance the further development of
products based on West&#146;s technologies. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The drug delivery business will
operate from West&#146;s facility in Nottingham, England, and will employ all of the
Division&#146;s employees at that location. Drug Delivery operations at West&#146;s
Lionville facility will wind down following the transaction. Approximately 30 jobs will be
eliminated and the Company has notified affected employees. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In June of 2004, the Company
announced that it would conduct a strategic review of its drug delivery business, and that
it intended to complete that process by the end of 2004. As a result of the pending
transaction, the Company will take a pre-tax charge estimated to be between $4.0 million
and $7.0 million, or between $0.08 and $0.16 per diluted share, substantially all of which
will be reported in the fourth quarter of 2004. This includes estimated impairment charges
associated with intangible assets related to both the drug delivery technologies and the
clinical services unit, and related costs for severance and other transaction costs. The
Company&#146;s Drug Delivery division will be classified as a &#147;discontinued
operation&#148; in the Company&#146;s subsequent financial reports, including its clinical
services business, which the Company will continue to operate while it is held for sale or
other disposition. The ownership interest in the new company will be accounted for on a
cost basis. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Donald E. Morel, PhD, West&#146;s
Chairman and Chief Executive Officer, commented, &#147;I am pleased that we have completed
the strategic review of options for the Drug Delivery Division and are able to announce
this transaction on our original schedule. This agreement will result in significant new
funding for the drug delivery technologies in partnership with world-class financial
sponsors who understand the market for these technologies, allowing us to participate in
the ultimate success of the business without committing further capital. This, in turn,
will focus management on building the long-term growth and profitability of West&#146;s
pharmaceutical systems businesses.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The charges associated with the Drug
Delivery division will lower the Company&#146;s GAAP earnings for the year. The Company is
affirming its earlier guidance for 2004 full year results and providing an update to give
effect to changes in how results will be reported for 2004. Because of the changes in the
Drug Delivery division, the Company&#146;s GAAP financial statements will reflect that
business segment&#146;s operating results for the year estimated to be between $0.31 and
$0.32 per diluted share as a &#147;discontinued operation&#148;, a separate component of
net income and earnings per share. A table included in this release reconciles the
Company&#146;s expected GAAP results, before the effects of the estimated charges
associated with the changes to the Drug Delivery division, the Company&#146;s prior
non-GAAP guidance of $1.00 to $1.05 per share and estimated earnings per share from
continuing operations of $1.31 to 1.37 per share. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Company&#146;s management will
hold a conference call to discuss this announcement and to respond to questions on
Tuesday, December 28, 2004 at 3:00 PM (E.S.T.). To access the call, dial 1-800-988-0221 or
1-712-271-3364, passcode is &#147;West&#148;. The call will be webcast live on the
Company&#146;s website at <U>www.westpharma.com</U>. A replay of the conference call will
be available within two hours of the live call and will remain available until January 11,
2005. To access the replay, dial 1-866-395-1642 or 1-203-369-0464, no passcode is needed
to access the replay. In addition, an archived webcast of the replay will be available on
the Company&#146;s website at <U>www.westpharma.com</U>. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<A NAME=A002></A>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>About West Pharmaceutical
Services, Inc. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>West Pharmaceutical Services, Inc. is
the world&#146;s leading manufacturer of components and systems for injectable drug
delivery, including stoppers and seals for vials, and closures and disposable components
used in syringe, IV and blood collection systems. West&#146;s customers include the
world&#146;s leading pharmaceutical, biotechnology, generic drug and medical device
producers. Internationally headquartered in Lionville, Pennsylvania, West supports its
partners and customers from 50 locations throughout North America, South America, Europe,
Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<A NAME=A003></A>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cautionary Statement
Regarding Forward-Looking Information </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain statements contained in this
press release or in other Company documents and certain statements that may be made by
management of the Company orally may contain forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. These statements can be identified by
the fact that they do not relate strictly to historic or current facts. They use words
such as &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;believe,&#148;
&#147;plan,&#148; &#147;anticipate&#148; and other words and terms of similar meaning in
connection with any discussion of future operating or financial performance or condition.
In particular, these include statements concerning future actions, future performance or
results of current and anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings and financial results. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Because actual results are affected
by risks and uncertainties, the Company cautions investors that actual results may differ
materially from those expressed or implied in any forward-looking statement.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
It is not
possible to predict or identify all such risks and uncertainties, but factors that could
cause the actual results to differ materially from expected and historical results
include, but are not limited to: successful completion of the disposition of the
Company&#146;s drug delivery technologies pursuant to the transactions described in this
release, including the Company&#146;s obtaining of necessary approvals and consents to the
transaction; the ability of the acquirer of the drug delivery technologies to develop and
market products based on those technologies; the Company&#146;s continued ability to
operate its clinical services business pending development and execution of a plan for
disposing of that business; sales demand, the timing of customers&#146; projects;
continued plant operating efficiencies; the Company&#146;s ability to maintain its market
position and pricing in the face of lower-cost competitors, particularly in the European
marketplace; the Company&#146;s ability to maintain a favorable mix of value-added
products in its portfolio; continued strong contribution from the Company&#146;s
affiliates; strength or weakness of the U.S. dollar; inflation; potential price increases
in raw materials, including those that are petroleum-based, and the continued availability
of raw materials; and the impact of recent tax legislation relating to repatriation of
foreign earnings.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
With respect to the explosion and fire at the Company&#146;s Kinston, NC
plant, the following factors should also be taken into consideration: delays in receiving
customer approvals of the facility and products produced there, and achieving
cost-efficient levels of production in the new facility; continuing costs associated with
the plant; the unpredictability of existing and future possible litigation related to the
explosion and the adequacy of insurance recoveries for costs associated with such
litigation; the impact of government actions or investigations affecting the Company; the
extent of uninsured costs for, among other things, legal and investigation services and
incremental insurance; and regulatory approvals and customer acceptance of goods from
alternate sites. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Company assumes no obligation to
update forward-looking statements as circumstances change. Investors are advised, however,
to consult any further disclosures the Company makes on related subjects in the
Company&#146;s 10-K, 10-Q and 8-K reports. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<A NAME=A004></A>
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>West Pharmaceutical
Services </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Minor Center Bold" FSL="Default" -->
<A NAME=A005></A>
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Reconciliation US GAAP
Earnings Per Share to Non-GAAP Earnings Per Share <BR>Including the reclassification of
Drug Delivery Systems to Discontinued Operations </FONT></H1>

<PRE>
                                               For the year ended December 31

                                                  2004 forecast           2003
                                                Low         High        Actual
                                               --------------------------------
Earnings per share, US GAAP basis,
including Drug Delivery Segment results        $ 0.65      $ 0.74      $ 1.10

Insurance settlement                               -            -       (0.42)

Restructuring and impairment charges             0.05        0.05        0.26

Kinston production and legal costs               0.32        0.28           -

Equity affiliate gain                           (0.02)      (0.02)          -
                                               --------------------------------
Earnings per share, Non-GAAP basis,
including Drug Delivery Segment results        $ 1.00      $ 1.05      $ 0.94

Reclassify Drug Delivery Systems Segment
operating results to Discontinued Operations *   0.31        0.32        0.42
                                               --------------------------------

Earnings per share of continuing operations,
Non-GAAP basis, excluding Drug Delivery        $ 1.31      $ 1.37      $ 1.36


</PRE>
<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Company believes the comparisons
of period-to-period results of its ongoing business operations are aided by excluding the
insurance settlement, related uninsured costs and on-going additional production and legal
costs associated with the 2003 plant explosion in Kinston N.C., and by excluding
restructuring and impairment charges connected with the planned closure of its UK medical
device facility. Non-GAAP results also exclude a gain on the sale of real estate by the
Company&#146;s affiliate in Mexico. In addition, the results of the Drug Delivery segment
will be reported as a discontinued operation in current and future filings. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>* does not include the loss on
disposal of the Drug Delivery segment, which is estimated to be between $0.08 and $0.16
per diluted share. </FONT></P>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
